N

Núcleo de Pesquisa Clínica do Rio Grande do Sul | Porto Alegre, Brazil

Research site
(Unclaimed)
Location
Rua Mostardeiro 5 Unidade 310 Bairro Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brazil
Site insights

Top conditions

Obesity (5 trials)

Overweight (4 trials)

Gastroparesis (3 trials)

Cardiovascular Diseases (2 trials)

Type 2 Diabetes Mellitus (2 trials)

Top treatments

LY3298176
Tirzepatide
Relamorelin
LY3502970
Orforglipron
Mirikizumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

6 of 11
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Enrolling
Crohn's Disease
Drug: Mirikizumab

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Enrolling
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-rela...

Active, not recruiting
Overweight or Obesity
Overweight
Drug: Placebo
Drug: Orforglipron

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide
Locations recently updated

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

Trial sponsors

Lilly logo

Lilly (8 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems